Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
197.2 EUR | +1.08% |
|
+0.87% | -8.07% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With a 2024 P/E ratio at 26.6 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.07% | 10.9B | - | ||
+34.14% | 51.12B | B- | ||
-6.54% | 39.4B | B | ||
+34.92% | 38.48B | A | ||
+12.62% | 26.36B | B- | ||
-12.11% | 26.22B | C | ||
-13.43% | 20.96B | B | ||
+43.73% | 14.02B | B+ | ||
+31.81% | 12.49B | C+ | ||
-4.54% | 11.61B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Ratings Charles River Laboratories International, Inc.